The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma

Journal of Immunology

Volumn 175, Issue 8, 2005, Pages 5351-5357

  Mestas, Javier ^a   Burdick, Marie D ^a   Reckamp, Karen ^a   Pantuck, Allan ^a   Figlin, Robert A ^a   Strieter, Robert M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR2; GAMMA INTERFERON INDUCIBLE PROTEIN 10; LIGAND; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLUORESCENCE ACTIVATED CELL SORTING; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 26844440862     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.175.8.5351     Document Type: Article

References (41)

1. Amato, R. J. 2005. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann. Oncol. 16: 7-15.
2. Chae, E. J., J. K. Kim, S. H. Kim, S. J. Bae, and K. S. Cho. 2005. Renal cell carcinoma: analysis of postoperative recurrence patterns. Radiology 234: 189-196.
3. George, D. J., and W. G. Kaelin, Jr. 2003. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N. Engl. J. Med. 349: 419-421.
4. Sufan, R. I., M. A. Jewett, and M. Ohh. 2004. The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma. Am. J. Physiol. 287: F1-F6.
5. 2, and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 107: 1-3.
6. Semenza, G. 2002. Signal transduction to hypoxia-inducible factor 1. Biochem. Pharmacol. 64: 993-998.
7. 2 homeostasis by hypoxia-inducible factor 1α. Genes Dev. 12: 149-162.
8. Carmeliet, P., Y. Dor, J. M. Herbert, D. Fukumura, K. Brusselmans, M. Dewerchin, M. Neeman, F. Bono, R. Abramovitch, P. Maxwell, et al. 1998. Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 394: 485-490.
9. Jiang, B. H., E. Rue, G. L. Wang, R. Roe, and G. L. Semenza. 1996. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J. Biol. Chem. 271: 17771-17778.
10. Yang, J. C., L. Haworth, R. M. Sherry, P. Hwu, D. J. Schwartzentruber, S. L. Topalian, S. M. Steinberg, H. X. Chen, and S. A. Rosenberg. 2003. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 349: 427-434.
11. Luan, J., R. Shattuck-Brandt, H. Haghnegahdar, J. D. Owen, R. Strieter, M. Burdick, C. Nirodi, D. Beauchamp, K. N. Johnson, and A. Richmond. 1997. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J. Leukocyte Biol. 62: 588-597.
12. Arenberg, D. A., M. P. Keane, B. DiGiovine, S. L. Kunkel, S. B. Morris, Y. Y. Xue, M. D. Burdick, M. C. Glass, M. D. Iannettoni, and R. M. Strieter. 1998. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J. Clin. Invest. 102: 465-472.
13. Arenberg, D. A., S. L. Kunkel, P. J. Polverini, M. Glass, M. D. Burdick, and R. M. Strieter. 1996. Inhibition of interleukin-8 reduces tumorigenesis of human non-small cell lung cancer in SCID mice. J. Clin. Invest. 97: 2792-2802.
14. Yatsunami, J., N. Tsuruta, K. Ogata, K. Wakamatsu, K. Takayama, M. Kawasaki, Y. Nakanishi, N. Hara, and S. Hayashi. 1997. Interleukin-8 participates in angiogenesis in non-small cell, but not small cell carcinoma of the lung. Cancer Lett. 120: 101-108.
15. Garkavtsev, I., S. V. Kozin, O. Chernova, L. Xu, F. Winkler, E. Brown, G. H. Barnett, and R. K. Jain. 2004. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 428: 328-332.
16. Clark-Lewis, I., B. Dewald, T. Geiser, B. Moser, and M. Baggiolini. 1993. Platelet factor 4 binds to interleukin 8 receptors and activates neutrophils when its N terminus is modified with Glu-Leu-Arg. Proc. Natl. Acad. Sci. USA 90: 3574-3577.
17. + CXC chemokine-induced angiogenic activity. J. Immunol. 165: 5269-5277.
18. Keane, M. P., J. A. Belperio, Y. Y. Xue, M. D. Burdick, and R. M. Strieter. 2004. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J. Immunol. 172: 2853-2860.
19. Belperio, J. A., M. P. Keane, M. D. Burdick, V. Londhe, Y. Y. Xue, K. Li, R. J. Phillips, and R. M. Strieter. 2002. Critical role for CXCR2 and CXCR2 ligands during the pathogenesis of ventilator-induced lung injury. J. Clin. Invest. 110: 1703-1716.
20. Phillips, R. J., M. D. Burdick, M. Lutz, J. A. Belperio, M. P. Keane, and R. M. Strieter. 2003. The stromal derived factor-1/CXCL12-CXC chemokine receptor 4 biological axis in non-small cell lung cancer metastases. Am. J. Respir. Crit. Care Med. 167: 1676-1686.
21. Belperio, J. A., M. Dy, M. D. Burdick, Y. Y. Xue, K. Li, J. A. Elias, and M. P. Keane. 2002. Interaction of IL-13 and C10 in the pathogenesis of bleomycin-induced pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 27: 419-427.
22. Keane, M. P., D. A. Arenberg, J. P. Lynch, III, R. I. Whyte, M. D. Iannettoni, M. D. Burdick, C. A. Wilke, S. B. Morris, M. C. Glass, B. DiGiovine, et al. 1997. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J. Immunol. 159: 1437-1443.
23. Keane, M. P., J. A. Belperio, T. A. Moore, B. B. Moore, D. A. Arenberg, R. E. Smith, M. D. Burdick, S. L. Kunkel, and R. M. Strieter. 1999. Neutralization of the CXC chemokine, macrophage inflammatory protein-2, attenuates bleomycin-induced pulmonary fibrosis. J. Immunol. 162: 5511-5518.
24. Keane, M. P., J. A. Belperio, D. A. Arenberg, M. D. Burdick, Z. J. Xu, Y. Y. Xue, and R. M. Strieter. 1999. IFN-γ-inducible protein-10 attenuates bleomycin-induced pulmonary fibrosis via inhibition of angiogenesis. J. Immunol. 163: 5686-5692.
25. Weber, J., V. K. Sondak, R. Scotland, R. Phillip, F. Wang, V. Rubio, T. B. Stuge, S. G. Groshen, C. Gee, G. G. Jeffery, et al. 2003. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer 97: 186-200.
26. Addison, C. L., D. A. Arenberg, S. B. Morris, Y. Y. Xue, M. D. Burdick, M. S. Mulligan, M. D. Iannettoni, and R. M. Strieter. 2000. The CXC chemokine, monokine induced by interferon-γ, inhibits non-small cell lung carcinoma tumor growth and metastasis. Hum. Gene Ther. 11: 247-261.
27. Arenberg, D. A., S. L. Kunkel, P. J. Polverini, S. B. Morris, M. D. Burdick, M. C. Glass, D. T. Taub, M. D. Iannettoni, R. I. Whyte, and R. M. Strieter. 1996. Interferon-γ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases. J. Exp. Med. 184: 981-992.
28. Addison, C. L., J. A. Belperio, M. D. Burdick, and R. M. Strieter. 2004. Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis. BMC Cancer 4: 28.
29. Koch, A. E., P. J. Polverini, S. L. Kunkel, L. A. Harlow, L. A. DiPietro, V. M. Einer, S. G. Einer, and R. M. Strieter. 1992. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 258: 1798-1801.
30. Strieter, R. M., S. L. Kunkel, V. M. Elner, C. L. Martonyi, A. E. Koch, P. J. Polverini, and S. G. Elner. 1992. Interleukin-8: a corneal factor that induces neovascularization. Am. J. Pathol. 141: 1279-1284.
31. Hu, D. E., Y. Hori, and T. P. Fan. 1993. Interleukin-8 stimulates angiogenesis in rats. Inflammation 17: 135-143.
32. Strieter, R. M., P. J. Polverini, S. L. Kunkel, D. A. Arenberg, M. D. Burdick, J. Kasper, J. Dzuiba, J. Van Damme, A. Walz, D. Marriott, et al. 1995. The functional role of the ELR motif in CXC chemokine-mediated angiogenesis. J. Biol. Chem. 270: 27348-27357.
33. Luster, A. D., S. M. Greenberg, and P. Leder. 1995. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation. J. Exp. Med. 182: 219-231.
34. Strieter, R. M., J. A. Belperio, M. D. Burdick, S. Sharma, S. M. Dubinett, and M. P. Keane. 2004. CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer. Ann. NY Acad. Sci. 1028: 351-360.
35. Moore, B. B., D. A. Arenberg, K. Stoy, T. Morgan, C. L. Addison, S. B. Morris, M. Glass, C. Wilke, Y. Y. Xue, S. Sitterding, et al. 1999. Distinct CXC chemokines mediate tumorigenicity of prostate cancer cells. Am. J. Pathol. 154: 1503-1512.
36. Murdoch, C., P. N. Monk, and A. Finn. 1999. CXC chemokine receptor expression on human endothelial cells. Cytokine 11: 704-712.
37. Chakrabarty, A., G. G. Hillman, R. L. Maughan, D. W. Visscher, E. AH, J. E. Pontes, and G. P. Haas. 1994. Influence of tumor site on the therapy of murine kidney cancer. Anticancer Res. 14: 373-378.
38. Moldobaeva, A., and E. M. Wagner. 2005. Difference in proangiogenic potential of systemic and pulmonary endothelium: role of CXCR2. Am. J. Physiol. 288: LI117-LI123.
39. Glade-Bender, J., J. J. Kandel, and D. J. Yamashiro. 2003. VEGF blocking therapy in the treatment of cancer. Expert Opin. Biol. Ther. 3: 263-276.
40. Kuenen, B. C., J. Tabernero, J. Baselga, F. Gavalli, E. Pfanner, P. F. Conte, S. Seeber, S. Madhusudan, G. Deplanque, H. Huisman, et al. 2003. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin. Cancer Res. 9: 1648-1655.
41. Kerbel, R. S., J. Yu, J. Tran, S. Man, A. Viloria-Petit, G. Klement, B. L. Coomber, and J. Rak. 2001. Possible mechanisms of acquired resistance to anti-angiogenic drugs: implications for the use of combination therapy approaches. Cancer Metastasis Rev. 20: 79-86.